NEA Secondary — Full Portfolio
8 tracked investments · listed companies and verified rows first
Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.
BiotechDeep TechMedical DevicesSouth San Francisco, US
Tim Lu(Co-Founder and Chief Executive Officer)inPhilip Lee(Executive Officer)Kanya Rajangam(President, Head of Research & Development and Chief Medical Officer)Yvonne Li(Executive Officer)James Collins(Director)
BoardDonald Tang(Director)
Board seatEdward Mathers· per SEC Form D · $40M raise · filed Jun 2026
Co-investorsEvolution VC PartnersFlucas VenturesLifeforce CapitalLux CapitalMenlo VenturesNew Enterprise Associates (NEA)+2 more
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.
AI & Machine LearningBiotechDeep TechWaltham, US
Luc Vandenberghe(Director)Rami Daoud(Executive Officer)Rick Modi(Chief Executive Officer, Board Member)Laura Richman(Executive Officer)Petra Kaufmann(Executive Officer)Robert Aboud(Executive Officer)
Board seatEdward Mathers· per SEC Form D · $45M raise · filed Oct 2025
Co-investorsAtlas VentureEcoR1 CapitalEight Roads VenturesF-Prime Capital PartnersGV (Google Ventures)New Enterprise Associates (NEA)+1 more
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)
BoardJill Carroll(Director)inDerek Yoon(Director)inTiba Aynechi(Director)in
Board seatAli Behbahani· per SEC Form D · $100M raise · filed Feb 2023
Co-investorsLG Technology VenturesNew Enterprise Associates (NEA)Quan CapitalSamsara BioCapitalSixty Degree CapitalSolasta Ventures+2 more
BiotechDover, US
Iain Dukes(Executive Officer, Director)Nikolay Savchuk(Executive Officer, Director)
BoardKeno Gutierrez(Director)Michele Cucullu(Director)
Board seatEdward Mathers· per SEC Form D · $65M raise · filed Jul 2024
Co-investorsNew Enterprise Associates (NEA)
HealthtechForest Lake, US
Steve Goedeke(Executive Officer, Director)
BoardKaren Shanahan(Director)William Abraham(Director)Michael DeMane(Director)Jay Graf(Director)
Board seatAli Behbahani· per SEC Form D · $11.5M raise · filed Oct 2021
Co-investorsAscension VenturesNew Enterprise Associates (NEA)
BiotechBurlington, US
Michael Mendelsohn(Executive Officer, Director)
BoardEvan Rachlin(Director)Peter Lawrence(Executive Officer, Director)Adam Koppel(Director)inNicholas Downing(Director)
Board seatEdward Mathers· per SEC Form D · $260.4M raise · filed Jul 2024
Co-investorsBain Capital Life SciencesBain CapitalPolaris PartnersThird Rock Ventures
BiotechSandy, US
Ciara Kennedy, Ph.D.(Executive Officer, Director)Brian Dorsey(Executive Officer)Michael Grey(Director)Mark Chin(Director)Susan Dube(Executive Officer)
Board seatEdward Mathers· per SEC Form D · $31.4M raise · filed Jan 2022
San Francisco, US
Rajaie Batniji(Executive Officer, Director)Sanjay Basu(Executive Officer, Director)
BoardVineeta Agarwala(Director)in
Board seatMohamad Makhzoumi· per SEC Form D · $22M raise · filed Nov 2023
Co-investorsAndreessen Horowitz
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.